Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Aug 26, 2015; 7(7): 1010-1021
Published online Aug 26, 2015. doi: 10.4252/wjsc.v7.i7.1010
Allogenic banking of dental pulp stem cells for innovative therapeutics
Pierre-Yves Collart-Dutilleul, Franck Chaubron, John De Vos, Frédéric J Cuisinier
Pierre-Yves Collart-Dutilleul, Frédéric J Cuisinier, BioNano Laboratory EA 4203, Montpellier 1 University, 34193 Montpellier Cedex5, France
Franck Chaubron, Institut Clinident BioPharma, Biopôle Clermont-Limagne, 63360 Saint Beauzire, France
John De Vos, INSERM U1040, Genetic Instability of Human Pluripotent Stem Cells, 34197 Montpellier, France
John De Vos, CHRU Montpellier, Hospital Saint-Eloi, Institut de Recherche en Biothérapie, 34197 Montpellier, France
Author contributions: Collart-Dutilleul PY, Chaubron F, De Vos J and Cuisinier FJ solely contributed to this paper.
Conflict-of-interest statement: The authors declare that they have no conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Frédéric J Cuisinier, DDS, PhD, BioNano Laboratory EA 4203, Montpellier 1 University, 545 Av Pr JL Viala, 34193 Montpellier Cedex5, France. frederic.cuisinier@univ-montp1.fr
Telephone: +33-4-11759225 Fax: +33-4-11759201
Received: October 13, 2014
Peer-review started: October 14, 2014
First decision: January 8, 2015
Revised: June 8, 2015
Accepted: June 18, 2015
Article in press: June 19, 2015
Published online: August 26, 2015
Processing time: 317 Days and 16.4 Hours
Core Tip

Core tip: To achieve clinical applications, stem cell-based therapy must shift from lab experimentation to clinical grade stem cells. We present here the development of advanced therapy medicinal products (ATMP) by the banking of dental pulp stem cells (DPSCs) for allogenic use. The dental pulp represents an efficient tool for industrial applications due to its accessibility after wisdom teeth extraction for orthodontic purpose. DPSC therapeutic batches can be produced in good manufacturing practice condition after human leukocyte antigen typing and stored in allogenic biobanks. We propose some clinical applications, for which there is no efficient therapeutics so far, but that DPSCs-based ATMP could potentially treat.